2.03

1.50% 0.03

After Hours: 2.01 -0.02 -0.99%

Inmune Bio Inc (INMB)

Overview News Price History Option Chain Financials Discussions Forecast

Inmune Bio Inc stock is traded at $2.03, with a volume of 193.63K. It is up +1.50% in the last 24 hours and down -16.46% over the past month. INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Previous Close:

$2.00

Open:

$2.01

24h Volume:

193.63K

Relative Volume:

0.27

Market Cap:

$56.34M

Revenue:

$50,000

Net Income/Loss:

$-41.60M

P/E Ratio:

-1.1979

EPS:

-1.6946

Net Cash Flow:

$-20.20M

1W Performance:

-12.88%

1M Performance:

-16.46%

6M Performance:

+66.39%

1Y Performance:

+0.00%

1-Day Range:

$1.96

$2.04

1-Week Range:

$1.94

$2.4199

52-Week Range:

$1.09

$2.60

Inmune Bio Inc Stock (INMB) Company Profile

Name

Inmune Bio Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(858) 964-3720

Address

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Employee

Twitter

@INmuneBio

Next Earnings Date

2026-10-29

Latest SEC Filings

INMB's Discussions on Twitter

Compare INMB vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INMB Inmune Bio Inc	2.03	56.34M	50,000	-41.60M	-20.20M	-1.6946
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Downgrade	BTIG Research	Buy → Neutral
Jul-01-25	Downgrade	Scotiabank	Sector Outperform → Sector Underperform
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Oct-21-24	Initiated	Alliance Global Partners	Buy
Sep-27-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Scotiabank	Sector Outperform
Jun-01-23	Initiated	Robert W. Baird	Outperform
May-24-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-21-21	Initiated	B. Riley Securities	Buy
Jan-22-21	Reiterated	Maxim Group	Buy
Sep-01-20	Initiated	BTIG Research	Buy
Jul-15-20	Reiterated	H.C. Wainwright	Buy

View All

Inmune Bio Inc Stock (INMB) Latest News

Sep 23, 2026

[Form 3] Inmune Bio, Inc. Initial Statement of Beneficial Ownership - Stock Titan

Sep 23, 2026

Sep 18, 2026

Inmune Stock Price Forecast. Should You Buy INMB? - StockInvest.us

Sep 18, 2026

Sep 17, 2026

Inmune Bio (NASDAQ: INMB) grants 100,000 stock options to new director - Stock Titan

Sep 17, 2026

Sep 16, 2026

New Inmune Bio (INMB) director reports no shares - Stock Titan

Sep 16, 2026

Sep 14, 2026

Inmune Bio Adds Strategic Directors to Support Commercialization - TipRanks

Sep 14, 2026

INmune Bio, Inc. Announces Board Appointments - marketscreener.com

Sep 14, 2026

INmune Bio at H.C. Wainwright conference: rdeB drug nears filings By Investing.com - Investing.com Canada

Sep 14, 2026

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board - Yahoo Finance

Sep 14, 2026

Sep 13, 2026

INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits

Sep 13, 2026

Sep 09, 2026

INmune Bio to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance

Sep 09, 2026

Sep 04, 2026